CoChat

Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

OBJECTIVES: Two identical, phase 3, randomized, double-blind, placebo-controlled trials evaluated the efficacy and safety of plecanatide in patients with irritable bowel syndrome with constipation (IBS-C). METHODS: Adults meeting Rome III criteria for IBS-C were randomized (1:1:1) to placebo or plecanatide (3 or 6 mg) for 12 weeks. The primary efficacy end point was the percentage of overall responders (patients reporting ≥30% reduction from baseline in worst abdominal pain plus an increase of ≥1 complete spontaneous bowel movement (CSBM)/week from baseline in the same week for ≥6 of 12 treatment weeks). Safety was assessed by adverse events (AEs). RESULTS: Overall, 2189 individuals were randomized across the two studies and 1879 completed the studies. Demographic and baseline characteristics were similar across treatment groups and between studies. The percentage of overall responders in Study 1 was 30.2% and 29.5% for plecanatide 3 and 6 mg, respectively, vs. 17.8% placebo (P < 0.001 for each dose vs. placebo), and in Study 2 was 21.5% (P = 0.009) and 24.0% (P < 0.001) for plecanatide 3 and 6 mg, respectively, compared to 14.2% for placebo. The percentage of sustained efficacy responders (overall responders plus weekly responders for ≥2 of last 4 weeks of the 12-week treatment period) was significantly greater for both doses of plecanatide vs. placebo across both studies. All secondary end points (stool frequency/consistency, straining, abdominal symptoms) showed statistically significant improvements compared with placebo. The most common AE was diarrhea (3 mg, 4.3%; 6 mg, 4.0%; placebo, 1.0%). Discontinuation due to diarrhea was infrequent (3 mg, 1.2%; 6 mg, 1.4%; placebo, 0). CONCLUSIONS: Plecanatide significantly improved both abdominal pain and constipation symptoms of IBS-C with minimal associated side effects and high levels of tolerability.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41395-018-0026-7

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 32 references

Research works printed but not linked: 2

  1. Doshi, 2014, J Manag Care Spec Pharm, 20, 382
  2. Tse, 2017, J Gastroenterol Hepatol, 2017, 8612189

Cited by

See all 145

Metadata

Authors
Brenner, D. M., Fogel, R., Dorn, S. D., Krause, R., Eng, P., Kirshoff, R., Nguyen, A., Crozier, R. A., Magnus, L., & Griffin, P. H.
Affiliations
Northwestern University (US)
Venue
American Journal of Gastroenterology
Published
2018-05
Volume
113
Issue
5
Pages
735-745
ISSN
0002-9270 (ISSN-L)
OpenAlex
W2792615508
Cited by
145
References
32
Citations by year
2026: 11 · 2025: 13 · 2024: 13 · 2023: 16 · 2022: 13 · 2021: 31 · 2020: 27 · 2019: 6 · 2018: 14
FWCI
18.59
Type
journal article
Language
en
Open access
closed
Locations
  • The American Journal of Gastroenterology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Allergan
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
  • Health Sciences › Medicine › Gastroenterology › Microscopic Colitis
Keywords
plecanatide, irritable bowel syndrome with constipation, guanylate cyclase-C agonist, abdominal pain, constipation, spontaneous bowel movements, stool frequency, straining, diarrhea, drug safety and tolerability
MeSH terms
Adult, Aged, Aged, 80 and over, Constipation, Defecation, Diarrhea, Dose-Response Relationship, Drug, Double-Blind Method, Female, Gastrointestinal Agents, Humans, Male, Middle Aged, Placebos, Abdominal Pain, Treatment Outcome, Irritable Bowel Syndrome, Natriuretic Peptides, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials. https://app.cochat.ai/papers/10.1038/s41395-018-0026-7
The paper
Brenner, D. M., Fogel, R., Dorn, S. D., Krause, R., Eng, P., Kirshoff, R., Nguyen, A., Crozier, R. A., Magnus, L., & Griffin, P. H. (2018). Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials. American Journal of Gastroenterology. https://doi.org/10.1038/s41395-018-0026-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.